Contract #HHSN272201800001I; SRI international; GMP manufacturing of oxfendazole clinical trial material and stability study; OA task 75N93021F00006; MIS task TOIA21C13PIPB-1; base award; can 8470036;…
Ended Awarded Last action
- Contract number
- 75N93021F00006
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $630,604
Award facts
- Contract value 100% obligated
- $630,604.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$4,219 | |
| Terminate for Convenience | $0 | |
| Exercise an Option | $72,349 | |
| Exercise an Option | $64,618 | |
| Exercise an Option | $110,881 | |
| Funding Only Action | $5,973 | |
| Other Administrative Action | $0 | |
| Original award | $381,002 |
About this award
The National Institute of Allergy and Infectious Diseases issued a delivery order to Sri International on July 27, 2021, with a ceiling value of $630,604.13 for GMP manufacturing of oxfendazole clinical trial material and stability study work under the Nonclinical Services for Development of Interventional Agents master IDIQ.
Place of performance is Menlo Park, CA. The order's ultimate completion date is June 2, 2025. Pricing is cost-plus-fixed-fee with no set-aside applied.
Service Contract Inventory reporting shows the order generated $3 thousand invoiced in FY2021 (0.1 FTEs, 106 contractor hours) at a derived rate of $31.23 per hour, scaling to $362 thousand in FY2022 (0.6 FTEs, 1,328 contractor hours) at $272.75 per hour, then declining through FY2024 to $87 thousand (0.1 FTEs, 255 contractor hours) at $340.09 per hour. FY2025 reported 0.1 FTEs and $80 thousand invoiced. Derived hourly rates rose across the reported period. Sri International self-performed all reported hours with no subcontractors engaged.
Description
Contract #HHSN272201800001I; SRI international; GMP manufacturing of oxfendazole clinical trial material and stability study; OA task 75N93021F00006; MIS task TOIA21C13PIPB-1; base award; can 8470036; total $381,002.00
Quick answers
Who was awarded contract 75N93021F00006?
75N93021F00006 was awarded to Sri International by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 27, 2021.
How much is contract 75N93021F00006 worth?
The government has obligated $630,604 on 75N93021F00006.
Is contract 75N93021F00006 an order under another contract?
Yes. 75N93021F00006 is a delivery order under 75N93018D00001, an indefinite delivery contract, on Nonclinical Services for Development of Interventional Agents.
Was contract 75N93021F00006 competed?
The extent of competition for 75N93021F00006 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award